<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206933</url>
  </required_header>
  <id_info>
    <org_study_id>GWUIRB #061012</org_study_id>
    <nct_id>NCT01206933</nct_id>
  </id_info>
  <brief_title>The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System</brief_title>
  <official_title>The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and
      Molecular Biology of The George Washington University Medical Center are carrying out a
      research study to determine why patients with Human Immunodeficiency Virus (HIV) and
      Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of
      HCV infection, leading to fatty infiltration of the liver and cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by the
      virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro hepatocyte
      model of hepatitis C infection to better understand the pathogenesis of HIV/HCV co-infection,
      and to gain insight into intracellular mechanisms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory analysis of Tat Protein</measure>
    <time_frame>Single sample analysis</time_frame>
    <description>The validation that HIV Tat protein is a potent inducer of HCV in dual infected patients will likely lead to anti-tat therapy to manage HCV patients for whom treatment options are rather limited.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Detectable HIV RNA and HCV RNA</arm_group_label>
    <description>HIV and HCV co-infected with detectable HIV RNA and HCV RNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undetectable HIV and Detectable HCV</arm_group_label>
    <description>HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undetectable HIV and HCV</arm_group_label>
    <description>HIV and HCV infected, Undetectable HIV RNA and HCV RNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undetectable HCV</arm_group_label>
    <description>HCV(mono-infected,) HCV RNA undetectable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Detectable HCV RNA</arm_group_label>
    <description>Monoinfected HCV, detectable RNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Detectable HIV RNA</arm_group_label>
    <description>Monoinfected HIV, Detectable RNA</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Four groups of subjects will be included in this study, with 5 participants in each group:

          1. detectable HIV RNA (Ribonucleic Acid) and detectable HCV RNA

          2. undetectable HIV RNA (treated) and detectable HCV RNA

          3. undetectable HIV RNA (treated) and undetectable HCV RNA

          4. undetectable HCV RNA (mono-infected)

          5. detectable HCV RNA (mono-infected)

          6. detectable HIV RNA (mono-infected)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets one of the following criteria:

               1. detectable HIV RNA and detectable HCV RNA

               2. undetectable HIV RNA (treated) and detectable HCV RNA

               3. undetectable HIV RNA (treated) and undetectable HCV RNA

               4. undetectable HCV RNA (mono-infected)

               5. detectable HCV RNA (mono-infected)

               6. detectable HIV RNA (mono-infected)

        Participants will be men and women, ages 18 and older, and who are patients being seen in
        the clinics of the Medical Faculty Associates, and meet the above criteria.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Parenti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV/HCV Coinfection</keyword>
  <keyword>Tat Protein</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

